. 2018 Aug 10;15:34. doi: 10.1186/s12989-018-0270-4

Table 10.

Change in physiological endpoints associated with IQR changes in target biomarkers

Biomarker	Physiological Parameters Change (95% CI)
Biomarker	Systolic BP (mmHg)	Diastolic BP (mmHg)	Heart Rate (bpm)
Adipsin	−1.94 (− 3.62, −0.26)*^a	0.38 (− 0.81, 1.04)^a	− 0.06 (− 1.62, 1.51)^a
CRP	0.40 (− 0.28, 1.08)^a	0.24 (− 0.27, 0.76)^a	1.13 (0.56, 1.69)*^b
IL-10	− 0.01 (− 0.85, 0.82)^a	− 0.15 (− 0.77, 0.47)^a	− 0.61 (− 1.33, 0.10)+^a
IL-12	− 0.07 (− 0.27, 0.14)^a	− 0.05 (− 0.20, 0.10)^a	− 0.25 (− 0.42, − 0.08)*^a
IL-6	0.08 (− 1.00, 1.15)^a	− 0.09 (− 0.09, 0.73)^a	− 1.09 (− 2.01, − 0.17)*^a
IL-7	− 0.14 (− 1.05, 0.76)^a	− 0.20 (− 0.88, 0.47)^a	− 0.68 (− 1.45, 0.10)+^a
PF4	− 1.57 (− 2.95, − 0.19)*^a	0.19 (− 0.87, 1.26)^a	0.03 (− 1.17, 1.24)^a
Plasma BET-1	1.41 (−0.59, 3.41)^a	− 1.22 (− 2.65, 0.20)*^c	−0.44 (− 2.17, 1.30)^a
Saliva BET-1	1.82 (0.64, 3.00)*^a	1.11 (0.08, 2.14)*^a	− 0.02 (− 1.21, 1.16)^a
Saliva ET-1(1–21)	1.78 (−0.25, 3.80)+^a	0.66 (− 0.94, 2.25)^a	− 1.01 (− 2.81, 0.80)^a
vWF	− 0.35 (− 1.25, 0.55)^a	0.77 (0.08, 1.45)*^c	−0.39 (− 1.22, 0.43)+^a

*p < 0.05; +p < 0.1(not significant, trend only)

^aCovariates: Treatment period, and carry over

^bCovariates:Treatment period, carry over, age, sex and BMI

^cCovariates: Treatment period, carry over, age, sex and BMI, atmospheric pressure, temperature, and relative humidity